PF-05231023

DRUG2 trials

Sponsors

Pfizer

Conditions

Diabetes Mellitus, Type 2

Phase 1

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

CompletedNCT01285518

PfizerDiabetes Mellitus, Type 2

Start: 2011-02-28End: 2011-07-31Updated: 2016-11-18

Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

CompletedNCT01396187

PfizerDiabetes Mellitus, Type 2

Start: 2011-07-31End: 2012-05-31Updated: 2015-01-12